Synthetic miR-34a against solid tumours: a predictable failure.
Sophie MocklyHervé SeitzPublished in: British journal of cancer (2022)
A prolific scientific literature attributes pro- or anti-oncogenic properties to many human microRNAs ("miRNAs"). While many of these studies are based on unpersuasive analyses, one candidate suppressor tumour miRNA, miR-34a, appeared convincing enough to be administered to human patients in a clinical trial-with disappointing outcomes. Here, we review possible reasons for that failure, and their implications for other miRNAs.
Keyphrases
- endothelial cells
- clinical trial
- cell proliferation
- long non coding rna
- end stage renal disease
- induced pluripotent stem cells
- long noncoding rna
- ejection fraction
- newly diagnosed
- systematic review
- chronic kidney disease
- pluripotent stem cells
- peritoneal dialysis
- prognostic factors
- type diabetes
- randomized controlled trial
- phase ii
- weight loss